Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

CompletedOBSERVATIONAL
Enrollment

403

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

July 22, 2024

Study Completion Date

July 26, 2024

Conditions
Overactive Bladder
Interventions
DRUG

Vibegron

Vibegron to be administered.

Trial Locations (64)

10016

Manhattan Medical Research Practice, PLLC, New York

10017

NYU Grossman School of Medicine, New York

10065

Weill Cornell Medical College, New York

11530

AccuMed Research Associates, Inc., Garden City

12603

Premier Medical Group of the Hudson Valley, PC, Poughkeepsie

13210

AMP Urology, Syracuse

14203

Circuit Clinical, Buffalo

18103

Institute for Female Pelvic Medicine, Allentown

19014

University of Pennsylvania, Philadelphia

19406

Center for Urogynecology and Pelvic Health, King of Prussia

21117

Chesapeake Urology Research Associates, Owings Mills

27103

Ardmore Family Practice, PA, Winston-Salem

Wake Forest Baptist Health, Winston-Salem

27403

Alliance Urology Specialists, Greensboro

27612

Associated Urologists of North Carolina, Raleigh

28207

Atrium Health Infectious Diseases Kenilworth, Charlotte

28345

FirstHealth Urogynecology, Hamlet

29169

Southern Urogynecology, West Columbia

29425

Medical University of South Carolina (MUSC), Charleston

30120

Georgia Urology, Cartersville

30328

WR-Mount Vernon Clinical Research, LLC, Sandy Springs

32209

University of Florida Health Jacksonville Facility Clinic, Jacksonville

33136

University of Miami Miller School of Medicine, Miami

33166

South Florida Research Phase I-IV, Inc., Miami Springs

33606

Tampa Urology Partners LLP, Tampa

33615

Florida Urology Partners, Tampa

33880

Clinical Research of Central Florida - Winter Haven, Winter Haven

44106

University Hospitals Cleveland Medical Center, Cleveland

44130

Clinical Research Solutions, Middleburg Heights

44195

Cleveland Clinic, Cleveland

45014

Obstetrics and Gynecology Associates, Inc., Cincinnati

45267

University of Cincinnati Physicians Obstetrics & Gynecology, Cincinnati

46123

American Health Network of Indiana, LLC, Avon

48602

Valley OB-GYN Clinic, PC, Saginaw

55455

Regents of the University of Minnesota, Minneapolis

56377

Adult & Pediatric Urology, Sartell

61801

Carle Foundation Hospital, Urbana

66160

The University of Kansas Health System, Kansas City

70115

DelRicht Research, New Orleans

71106

Regional Urology, LLC, Shreveport

72211

Arkansas Urology Associates, PA, Little Rock

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75246

Urology Clinics of North Texas, Dallas

76017

Urology Partners, Arlington

77479

Medicus Alliance Clinical Research Organization Inc., Sugar Land

78613

Medicus Alliance Clinical Research Organization Inc., Cedar Park

78681

North Austin Urology, Round Rock

83642

Idaho Urologic Institute, Meridian

84405

Advanced Research Institute, Ogden

85051

43rd Medical Associates, Phoenix

85283

Fiel Family and Sports Medicine, PC, Tempe

89128

SVG Clinical, Las Vegas

94705

Golden Gate Urology, Berkley

35209-5603

Urology Centers of Alabama, Homewood

06850

Urology Associates of Norwalk, Norwalk

33016-1815

Urological Research Network, Hialeah

60153-3328

Loyola University Medical Center, Maywood

01805

Lahey Hospital and Medical Center, Burlington

02472

Bay State Clinical Trials, Inc., Watertown

07003

New Jersey Urology Cancer Treatment Center, Bloomfield

08648

Lawrence OB-GYN Associates, P.C., Lawrenceville

08901

Rutgers - Robert Wood Johnson Medical School, New Brunswick

45211-6301

TriHealth, Cincinnati

26506-9186

West Virginia University, Morgantown

All Listed Sponsors
lead

Urovant Sciences GmbH

INDUSTRY

NCT05067478 - Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB) | Biotech Hunter | Biotech Hunter